Treatment News : FDA OKs Switching From Stable HIV Regimen to Complera

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 17, 2013

FDA OKs Switching From Stable HIV Regimen to Complera

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ coformulated triple antiretroviral (ARV) combination tablet Complera (emtricitabine/rilpivirine/tenofovir) for those HIV-positive adults who switch from a stable ARV regimen.

“Complera is an effective single-pill therapy with a demonstrated safety profile, and has rapidly become an important option for appropriate HIV patients who are initiating antiretroviral treatment,” Calvin J. Cohen, MD, MSc, research director of the Community Research Initiative of New England and an investigator on clinical trials of Complera, said in a release. “The data supporting today’s approval demonstrate Complera has the potential to help a broader range of HIV-infected patients who have achieved virologic control on another regimen.”

Those who switch their HIV regimen to Complera should never have experienced virologic failure, have at least six months of an undetectable viral load, and never have had resistance to the drugs in Complera.

The FDA approval is a result of the randomized, open-label Phase III SPIRIT clinical trial, in which participants with fully suppressed viral loads who were taking ritonavir-boosted, protease inhibitor–based multidrug ARV regimens either switched to Complera or remained on their same regimen. After 48 weeks of Complera, 89 percent (283/317) of the participants in the switching arm had a fully suppressed viral load, compared with 90 percent (143/159) of those in the protease inhibitor arm, who were followed for 24 weeks.

To read the Gilead release, click here.

Search: U.S. Food & Drug Administration, FDA, Gilead Sciences, Complera, emtricitabine, rilpivirine, tenofovir, HIV, Calvin J. Cohen, switch.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    zeze42
    Bay Area - Peninsula
    California


    Sexynyrican
    Brooklyn
    New York


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.